DexCom, Inc. (DXCM)
| Market Cap | 51.77B |
| Revenue (ttm) | 3.62B |
| Net Income (ttm) | 541.50M |
| Shares Out | 385.52M |
| EPS (ttm) | 1.30 |
| PE Ratio | 103.31 |
| Forward PE | 75.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,114,880 |
| Open | 134.36 |
| Previous Close | 133.86 |
| Day's Range | 133.58 - 135.99 |
| 52-Week Range | 74.75 - 142.00 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 140.79 (+4.83%) |
| Earnings Date | Apr 25, 2024 |
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into t... [Read more]
Financial Performance
In 2023, DexCom's revenue was $3.62 billion, an increase of 24.49% compared to the previous year's $2.91 billion. Earnings were $541.50 million, an increase of 58.70%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price forecast is $140.79, which is an increase of 4.83% from the latest price.
News
SLB, DXCM, CRH: The Economy is Relatively Healthy
Economic trends and earnings continue to drive most of the conversations, notes Tyler Ellegard. He discusses the impact upcoming earnings could have on the markets.
MD Revolution Partners with Dexcom to Integrate Continuous Glucose Monitoring Systems With its Remote Care Management Platform
SAN DIEGO--(BUSINESS WIRE)--MD Revolution, the leader in remote care management solutions for health systems and multi-specialty clinics, has partnered with Dexcom to integrate their industry-leading ...
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Dexcom Publishes Annual Sustainability Report
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This repo...
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will...
Neutral to Bullish on TTD, DXCM & Bullish on AMZN
The Trade Desk (TTD), Amazon (AMZN), and DexCom (DXCM) are today's big three stocks. Jessica Inskip and Rick Ducat discuss the technical trends, as well as how to trade these names.
Final Trades: SL Green, Palantir and Dexcom
The Investment Committee share their Final Trades.
Dexcom announces its first ever over-the-counter CGM Stelo has been cleared by the FDA
Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA.
US FDA clears use of first over-the-counter continuous glucose monitor
The U.S. Food and Drug Administration has cleared the use of Dexcom's device making it the first continuous glucose monitor to be available over the counter, the health regulator said on Tuesday.
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical eviden...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual R...
Tiger Global slashes stakes in Magnificent Seven while piling into semiconductor makers
Tiger Global has slashed its positions in four of the five Magnificent Seven tech stocks that account for almost half of its portfolio, while upping its stake in Amazon.com and piling into semiconduct...
Dexcom beats profit estimates on strong demand for glucose monitors
Glucose monitor maker Dexcom beat analyst estimates for fourth-quarter earnings on Thursday, helped by strong demand for its continuous glucose monitoring (CGM) systems.
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results.
Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of ...
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 20...
Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland
GALWAY, Ireland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new stat...
Charts turn bullish on health-care stocks as sector takes early lead in 2024
Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h...
A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose...
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
SAN DIEGO--(BUSINESS WIRE)---- $DXCM #Dexcom--Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook.
3 Medical-Device Stocks Could Click in 2024
Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. ...
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitor...
'Ten-bagger' stocks are the 'holy grail': Strategist
As Wall Street weighs whether markets can sustain November's rally, investors are spotting opportunities. eToro Global Markets Strategist Ben Laidler joined Yahoo Finance Live to analyze high-growth "...